(+)-Norfenfluramine-Induced Arterial Contraction Is Not Dependent on Endogenous 5-Hydroxytryptamine or 5-Hydroxytryptamine Transporter
- Wei Ni,
- Claudia S. Wilhelm,
- Michael Bader,
- Dennis L. Murphy,
- Keith Lookingland and
- Stephanie W. Watts
- Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (W.N., K.L., S.W.W.); Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany (C.S.W., M.B.); and Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland (D.L.M.)
- Address correspondence to:
Dr. Wei Ni, Department of Pharmacology and Toxicology, B445 Life Sciences Bldg., Michigan State University, East Lansing, MI 48824-1317. E-mail: niwei{at}msu.edu
Abstract
(+)-Norfenfluramine, the major metabolite of fenfluramine, causes vasoconstriction dependence on the 5-hydroxytryptamine (5-HT)2A receptor in rat. (+)-Norfenfluramine was reported as a 5-hydroxytryptamine transporter (5-HTT) substrate and 5-HT releaser. Because the arterial 5-HTT exists and is functional in the rat, we hypothesized that (+)-norfenfluramine causes vasoconstriction by releasing 5-HT from vascular smooth muscle via 5-HTT. The released 5-HT, in turn, activates the 5-HT2A receptor. Isometric contractility experiments showed that (+)-norfenfluramine-induced mouse aortic contraction was reduced by the 5-HTT inhibitor fluoxetine (1 μM) but not by fluvoxamine (1 μM). Tryptophan hydroxylase (TPH)-deficient (Tph1–/–) mice lack peripheral 5-HT. (+)-Norfenfluramine (10 nM–100 μM)-contracted aorta from wild-type and Tph1–/– mice with equivalent potency (–log EC50 [M], wild type = 5.73 ± 0.02, Tph1–/– = 5.62 ± 0.09), and these contractions were inhibited by the 5-HT2A receptor antagonist ketanserin (3 nM) by a similar magnitude in aorta from wild-type and Tph1–/– mice (wild type = 19.4, Tph1–/– = 15.4-fold rightward shift versus control), as did fluoxetine (1 μM) (wild type = 22.4, Tph1–/– = 28.8-fold rightward shift versus control). To further test the role of 5-HTT in (+)-norfenfluramine-induced aortic contraction, the 5-HTT-targeted mutation mouse was used. (+)-Norfenfluramine induced similar aortic contraction in wild-type and 5-HTT-targeted mutation mice, and these contractions were inhibited by fluoxetine (1 μM). Thus, (+)-norfenfluramine vasoconstriction is not dependent on 5-HTT-mediated release of endogenous 5-HT but by activating membrane 5-HT2A receptors directly. Understanding of the mechanism by which (+)-norfenfluramine induces vasoconstriction is important to characterize and understand the function of the serotonergic system in peripheral arterial vasculature.
Footnotes
-
This study was supported by National Institutes of Health Grant HL58489 and American Heart Association Grant 0415397Z.
-
doi:10.1124/jpet.105.087080.
-
ABBREVIATIONS: 5-HT, 5-hydroxytryptamine; 5-HTT, 5-hydroxytryptamine transporter; TPH, tryptophan hydroxylase; HPLC, high-pressure liquid chromatography; 5-HIAA, 5-hydroxyindole acetic acid; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; OCT, organic cation transporter; PSS, physiological salt solution; 5-HTT KO, 5-HTT-targeted mutation mouse; NET, norepinephrine transporter.
-
- Received March 31, 2005.
- Accepted May 12, 2005.
- The American Society for Pharmacology and Experimental Therapeutics



